Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

Article Medicine, General & Internal

Homologous and Heterologous Covid-19 Booster Vaccinations

R. L. Atmar et al.

Summary: This study investigated the efficacy of homologous and heterologous booster vaccines in adults who had completed a primary Covid-19 vaccine regimen. The results showed that both types of booster vaccines were safe and immunogenic.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

Rolando Pajon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Multidisciplinary Sciences

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Peter B. Gilbert et al.

Summary: In the COVE phase 3 clinical trial, neutralizing and binding antibodies were measured in vaccine recipients to determine their correlation with COVID-19 risk and vaccine efficacy. The results showed that these immune markers were inversely associated with COVID-19 risk and directly associated with vaccine efficacy. Postvaccination neutralization titers of 10, 100, and 1000 correlated with estimated vaccine efficacies of 78%, 91%, and 96% respectively.

SCIENCE (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

Jill M. Ferdinands et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Article Immunology

Augmented neutralization of SARS-CoV-2 Omicron variant by boost vaccination and monoclonal antibodies

Sebastian R. Schulz et al.

Summary: In this study, the efficacy of boost immunization with BNT162b2 and therapeutic antibodies in neutralizing the Omicron variant was determined using flow cytometry-based assays. The results showed that a third vaccination with BNT162b2 increased the amount of neutralizing antibodies against the Omicron variant, although to a lesser degree compared to the parental strain. Additionally, most clinically approved therapeutic antibodies failed to recognize and neutralize the Omicron variant, while some antibodies under preclinical development showed potential in neutralizing it.

EUROPEAN JOURNAL OF IMMUNOLOGY (2022)

Add to Collection

Article Immunology

Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant

Aurelien Sokal et al.

Summary: The Omicron variant of SARS-CoV-2 is able to escape neutralization by antibodies elicited by vaccines and previous infection. However, the memory B cells (MBCs) generated by mRNA vaccines can still recognize and neutralize the Omicron variant to some extent, providing a certain level of protection for vaccinated individuals.

IMMUNITY (2022)

Add to Collection

Article Immunology

Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant

Kevin K. Arien et al.

Summary: This study reports the levels of neutralizing antibodies against Wuhan, Delta, and Omicron variants in different groups of individuals. The findings support the use of booster vaccines to prevent infection and disease caused by the Omicron variant.

NPJ VACCINES (2022)

Add to Collection

Article Cell Biology

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant

Venkata-Viswanadh Edara et al.

Summary: The study indicates that a two-dose vaccination may not provide sufficient neutralizing antibody responses against the omicron variant, with a significant reduction in neutralizing activity observed after six months. However, COVID-19-recovered individuals still retain some level of neutralizing antibody responses. A third dose (booster shot) is necessary to enhance the neutralizing activity against the omicron variant.

CELL REPORTS MEDICINE (2022)

Add to Collection

Letter Medicine, General & Internal

Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines

Ai-ris Y. Collier et al.

Summary: The kinetics of immune response to Covid-19 vaccines were studied, showing varying peak levels and durations of response for different vaccines. However, the response levels correlating with protection have not been defined yet.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Microbiology

Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

Venkata Viswanadh Edara et al.

Summary: Despite reduced antibody titers against the B.1.351 variant, sera from infected and vaccinated individuals containing polyclonal antibodies to the spike protein could still neutralize SARS-CoV-2 B.1.351, suggesting that protective humoral immunity may be retained against this variant.

CELL HOST & MICROBE (2021)

Add to Collection

Letter Medicine, General & Internal